Literature DB >> 28612291

[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging.

Marta Marquié1,2, Michael Siao Tick Chong1,2, Alejandro Antón-Fernández1,2, Eline E Verwer3, Nil Sáez-Calveras1,2, Avery C Meltzer1,2, Prianca Ramanan1,2, Ana C Amaral1,2, Jose Gonzalez1,2,4, Marc D Normandin3, Matthew P Frosch1,2,4, Teresa Gómez-Isla5,6.   

Abstract

[F-18]-AV-1451, a PET tracer specifically developed to detect brain neurofibrillary tau pathology, has the potential to facilitate accurate diagnosis of Alzheimer's disease (AD), staging of brain tau burden and monitoring disease progression. Recent PET studies show that patients with mild cognitive impairment and AD dementia exhibit significantly higher in vivo [F-18]-AV-1451 retention than cognitively normal controls. Importantly, PET patterns of [F-18]-AV-1451 correlate well with disease severity and seem to match the predicted topographic Braak staging of neurofibrillary tangles (NFTs) in AD, although this awaits confirmation. We studied the correlation of autoradiographic binding patterns of [F-18]-AV-1451 and the stereotypical spatiotemporal pattern of progression of NFTs using legacy postmortem brain samples representing different Braak NFT stages (I-VI). We performed [F-18]-AV-1451 phosphor-screen autoradiography and quantitative tau measurements (stereologically based NFT counts and biochemical analysis of tau pathology) in three brain regions (entorhinal cortex, superior temporal sulcus and visual cortex) in a total of 22 cases: low Braak (I-II, n = 6), intermediate Braak (III-IV, n = 7) and high Braak (V-VI, n = 9). Strong and selective [F-18]-AV-1451 binding was detected in all tangle-containing regions matching precisely the observed pattern of PHF-tau immunostaining across the different Braak stages. As expected, no signal was detected in the white matter or other non-tangle containing regions. Quantification of [F-18]-AV-1451 binding was very significantly correlated with the number of NFTs present in each brain region and with the total tau and phospho-tau content as reported by Western blot and ELISA. [F-18]-AV-1451 is a promising biomarker for in vivo quantification of brain tau burden in AD. Neuroimaging-pathologic studies conducted on postmortem material from individuals imaged while alive are now needed to confirm these observations.

Entities:  

Keywords:  Alzheimer; Braak staging; Neurofibrillary tangles; PET; Tau; [F-18]-AV-1451

Mesh:

Substances:

Year:  2017        PMID: 28612291      PMCID: PMC5772971          DOI: 10.1007/s00401-017-1740-8

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  31 in total

1.  In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum.

Authors:  Hanna Cho; Jae Yong Choi; Mi Song Hwang; You Jin Kim; Hye Mi Lee; Hye Sun Lee; Jae Hoon Lee; Young Hoon Ryu; Myung Sik Lee; Chul Hyoung Lyoo
Journal:  Ann Neurol       Date:  2016-07-08       Impact factor: 10.422

2.  Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms: Modeling Using an Autopsy Cohort and Application to Clinical Trial Design.

Authors:  Jing Qian; Bradley T Hyman; Rebecca A Betensky
Journal:  JAMA Neurol       Date:  2017-05-01       Impact factor: 18.302

Review 3.  Neuropathological alterations in Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Matthew P Frosch; Eliezer Masliah; Bradley T Hyman
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

Review 4.  Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Authors:  Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2012-05       Impact factor: 3.685

5.  Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study.

Authors:  Kathryn P Riley; David A Snowdon; William R Markesbery
Journal:  Ann Neurol       Date:  2002-05       Impact factor: 10.422

6.  Tau positron emission tomographic imaging in aging and early Alzheimer disease.

Authors:  Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling
Journal:  Ann Neurol       Date:  2015-12-15       Impact factor: 10.422

7.  Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias.

Authors:  Kerstin Sander; Tammaryn Lashley; Priya Gami; Thibault Gendron; Mark F Lythgoe; Jonathan D Rohrer; Jonathan M Schott; Tamas Revesz; Nick C Fox; Erik Årstad
Journal:  Alzheimers Dement       Date:  2016-02-15       Impact factor: 21.566

8.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop.

Authors:  Ian G McKeith
Journal:  J Alzheimers Dis       Date:  2006       Impact factor: 4.472

9.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

10.  Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

Authors:  Michael J Pontecorvo; Michael D Devous; Michael Navitsky; Ming Lu; Stephen Salloway; Frederick W Schaerf; Danna Jennings; Anupa K Arora; Anne McGeehan; Nathaniel C Lim; Hui Xiong; Abhinay D Joshi; Andrew Siderowf; Mark A Mintun
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

View more
  45 in total

1.  Imaging of tau deposits in adults with Niemann-Pick type C disease: a case-control study.

Authors:  Victor L Villemagne; D Velakoulis; V Doré; S Bozinoski; C L Masters; C C Rowe; Mark Walterfang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-28       Impact factor: 9.236

2.  [18F]-AV-1451 tau PET imaging in Alzheimer's disease and suspected non-AD tauopathies using a late acquisition time window.

Authors:  Julien Lagarde; Pauline Olivieri; Fabien Caillé; Philippe Gervais; Jean-Claude Baron; Michel Bottlaender; Marie Sarazin
Journal:  J Neurol       Date:  2019-09-18       Impact factor: 4.849

3.  Tau Imaging: New Era of Neuroimaging for Alzheimer's Disease.

Authors:  Jae Seung Kim
Journal:  Nucl Med Mol Imaging       Date:  2020-07-27

Review 4.  The complexity of tau in Alzheimer's disease.

Authors:  Nima N Naseri; Hong Wang; Jennifer Guo; Manu Sharma; Wenjie Luo
Journal:  Neurosci Lett       Date:  2019-04-25       Impact factor: 3.046

Review 5.  Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.

Authors:  Victor L Villemagne; Vincent Doré; Samantha C Burnham; Colin L Masters; Christopher C Rowe
Journal:  Nat Rev Neurol       Date:  2018-02-16       Impact factor: 42.937

6.  Corticobasal degeneration: key emerging issues.

Authors:  F Ali; K A Josephs
Journal:  J Neurol       Date:  2017-10-23       Impact factor: 4.849

Review 7.  Neuropathological assessment of the Alzheimer spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2020-08-01       Impact factor: 3.575

8.  Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.

Authors:  Pierre-François Meyer; Alexa Pichet Binette; Julie Gonneaud; John C S Breitner; Sylvia Villeneuve
Journal:  JAMA Neurol       Date:  2020-04-01       Impact factor: 18.302

9.  Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.

Authors:  Alexandre Bejanin; Daniel R Schonhaut; Renaud La Joie; Joel H Kramer; Suzanne L Baker; Natasha Sosa; Nagehan Ayakta; Averill Cantwell; Mustafa Janabi; Mariella Lauriola; James P O'Neil; Maria L Gorno-Tempini; Zachary A Miller; Howard J Rosen; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  Brain       Date:  2017-12-01       Impact factor: 13.501

10.  Widespread distribution of tauopathy in preclinical Alzheimer's disease.

Authors:  Stephanie A Schultz; Brian A Gordon; Shruti Mishra; Yi Su; Richard J Perrin; Nigel J Cairns; John C Morris; Beau M Ances; Tammie L S Benzinger
Journal:  Neurobiol Aging       Date:  2018-09-01       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.